227 related articles for article (PubMed ID: 14996724)
1. A genetically defined model for human ovarian cancer.
Liu J; Yang G; Thompson-Lanza JA; Glassman A; Hayes K; Patterson A; Marquez RT; Auersperg N; Yu Y; Hahn WC; Mills GB; Bast RC
Cancer Res; 2004 Mar; 64(5):1655-63. PubMed ID: 14996724
[TBL] [Abstract][Full Text] [Related]
2. Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications.
Shan W; Mercado-Uribe I; Zhang J; Rosen D; Zhang S; Wei J; Liu J
Cell Cycle; 2012 Jun; 11(11):2107-13. PubMed ID: 22592533
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells.
Yang G; Rosen DG; Mercado-Uribe I; Colacino JA; Mills GB; Bast RC; Zhou C; Liu J
Carcinogenesis; 2007 Jan; 28(1):174-82. PubMed ID: 16829690
[TBL] [Abstract][Full Text] [Related]
4. Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model.
Young T; Mei F; Liu J; Bast RC; Kurosky A; Cheng X
Oncogene; 2005 Sep; 24(40):6174-84. PubMed ID: 15940260
[TBL] [Abstract][Full Text] [Related]
5. Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras.
MacKenzie KL; Franco S; Naiyer AJ; May C; Sadelain M; Rafii S; Moore MA
Oncogene; 2002 Jun; 21(27):4200-11. PubMed ID: 12082607
[TBL] [Abstract][Full Text] [Related]
6. RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells.
Mei FC; Young TW; Liu J; Cheng X
FASEB J; 2006 Mar; 20(3):497-9. PubMed ID: 16384911
[TBL] [Abstract][Full Text] [Related]
7. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
8. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.
Karst AM; Levanon K; Drapkin R
Proc Natl Acad Sci U S A; 2011 May; 108(18):7547-52. PubMed ID: 21502498
[TBL] [Abstract][Full Text] [Related]
9. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD
Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012
[TBL] [Abstract][Full Text] [Related]
10. Proteomics analyses of ovarian cancer using genetically defined human ovarian cancer models.
Cheng X; Young TW; Mei FC
Front Biosci; 2007 Sep; 12():5166-74. PubMed ID: 17569638
[TBL] [Abstract][Full Text] [Related]
11. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
[TBL] [Abstract][Full Text] [Related]
12. Immortalisation of human ovarian surface epithelium with telomerase and temperature-sensitive SV40 large T antigen.
Davies BR; Steele IA; Edmondson RJ; Zwolinski SA; Saretzki G; von Zglinicki T; O'Hare MJ
Exp Cell Res; 2003 Aug; 288(2):390-402. PubMed ID: 12915130
[TBL] [Abstract][Full Text] [Related]
13. Resistance to mutant KRAS
Muraki N; Yamada M; Doki H; Nakai R; Komeda K; Goto D; Kawabe N; Matsuoka K; Matsushima M; Kawabe T; Tanaka I; Morise M; Shay JW; Minna JD; Sato M
Exp Cell Res; 2022 May; 414(1):113053. PubMed ID: 35149086
[TBL] [Abstract][Full Text] [Related]
14. Signaling and transcriptional changes critical for transformation of human cells by simian virus 40 small tumor antigen or protein phosphatase 2A B56gamma knockdown.
Moreno CS; Ramachandran S; Ashby DG; Laycock N; Plattner CA; Chen W; Hahn WC; Pallas DC
Cancer Res; 2004 Oct; 64(19):6978-88. PubMed ID: 15466190
[TBL] [Abstract][Full Text] [Related]
15. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers.
Lawrenson K; Sproul D; Grun B; Notaridou M; Benjamin E; Jacobs IJ; Dafou D; Sims AH; Gayther SA
Carcinogenesis; 2011 Oct; 32(10):1540-9. PubMed ID: 21859834
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between human telomerase reverse transcriptase transcriptional level and telomerase activity in three ovarian cancer cell lines].
Song Y; Kong BH; Liu PS; Ma DX; Jiang S
Ai Zheng; 2003 May; 22(5):486-91. PubMed ID: 12753708
[TBL] [Abstract][Full Text] [Related]
17. Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry.
Young TW; Mei FC; Yang G; Thompson-Lanza JA; Liu J; Cheng X
Cancer Res; 2004 Jul; 64(13):4577-84. PubMed ID: 15231669
[TBL] [Abstract][Full Text] [Related]
18. The use of transformed IMR90 cell model to identify the potential extra-telomeric effects of hTERT in cell migration and DNA damage response.
Cao X; Kong CM; Mathi KM; Lim YP; Cacheux-Rataboul V; Wang X
BMC Biochem; 2014 Aug; 15():17. PubMed ID: 25098897
[TBL] [Abstract][Full Text] [Related]
19. RIF1 promotes human epithelial ovarian cancer growth and progression via activating human telomerase reverse transcriptase expression.
Liu YB; Mei Y; Long J; Zhang Y; Hu DL; Zhou HH
J Exp Clin Cancer Res; 2018 Aug; 37(1):182. PubMed ID: 30075819
[TBL] [Abstract][Full Text] [Related]
20. Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer.
Rosen DG; Yang G; Bast RC; Liu J
Methods Enzymol; 2006; 407():660-76. PubMed ID: 16757360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
